Posted by Michael Wonder on 26 Aug 2020
ICER releases draft evidence report on therapies for haemophilia A
26 August 2020 - Public comment period now open until 23 September 2020; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for haemophilia A; this assessment includes valoctocogene roxaparvovec (Roctavian, BioMarin Pharmaceutical) and emicizumab (Hemlibra, Genentech).
ICER is proceeding with this assessment despite the complete response letter that BioMarin Pharmaceutical recently received from the FDA. This preliminary draft marks the midpoint of ICER’s eight month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
